SunTrust Banks Inc. downgraded shares of Juno Therapeutics Inc (NASDAQ:JUNO) from a buy rating to a hold rating in a report issued on Friday morning. They currently have $25.00 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $48.00.

Several other research firms have also issued reports on JUNO. Maxim Group dropped their price target on Juno Therapeutics from $80.00 to $50.00 and set a buy rating on the stock in a research report on Friday, August 5th. BTIG Research raised Juno Therapeutics from a sell rating to a neutral rating in a research report on Thursday, November 3rd. FBR & Co reissued an outperform rating and set a $61.00 price target on shares of Juno Therapeutics in a research report on Saturday, October 15th. Standpoint Research initiated coverage on Juno Therapeutics in a research report on Thursday, August 25th. They set a buy rating and a $47.00 price target on the stock. Finally, Vetr lowered Juno Therapeutics from a strong-buy rating to a buy rating and set a $38.02 target price on the stock. in a research report on Monday, August 22nd. Six analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Juno Therapeutics presently has a consensus rating of Buy and an average price target of $40.40.

Juno Therapeutics (NASDAQ:JUNO) opened at 20.05 on Friday. The firm’s market cap is $2.06 billion. Juno Therapeutics has a 1-year low of $19.41 and a 1-year high of $57.82. The stock’s 50 day moving average price is $27.32 and its 200 day moving average price is $32.73.

Juno Therapeutics (NASDAQ:JUNO) last posted its quarterly earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.57) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by $0.05. The company earned $20.80 million during the quarter, compared to analyst estimates of $10.98 million. The company’s quarterly revenue was up 1200.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.26) earnings per share. Equities research analysts predict that Juno Therapeutics will post ($2.54) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece was originally published by Daily Political and is the propert of of Daily Political. If you are accessing this piece on another site, it was illegally copied and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at http://www.dailypolitical.com/2016/11/30/suntrust-banks-inc-lowers-juno-therapeutics-inc-juno-to-hold.html.

In related news, CEO Hans Edgar Bishop sold 84,035 shares of the firm’s stock in a transaction dated Wednesday, September 21st. The stock was sold at an average price of $30.28, for a total transaction of $2,544,579.80. Following the completion of the transaction, the chief executive officer now owns 2,518,537 shares of the company’s stock, valued at $76,261,300.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Robert Azelby sold 12,921 shares of the firm’s stock in a transaction dated Thursday, November 10th. The shares were sold at an average price of $24.14, for a total value of $311,912.94. Following the transaction, the executive vice president now directly owns 48,640 shares of the company’s stock, valued at approximately $1,174,169.60. The disclosure for this sale can be found here.

A number of hedge funds and other institutional investors have recently made changes to their positions in JUNO. D.A. Davidson & CO. boosted its position in shares of Juno Therapeutics by 40.8% in the third quarter. D.A. Davidson & CO. now owns 16,918 shares of the biopharmaceutical company’s stock valued at $507,000 after buying an additional 4,900 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Juno Therapeutics by 0.4% in the third quarter. Price T Rowe Associates Inc. MD now owns 23,698 shares of the biopharmaceutical company’s stock valued at $711,000 after buying an additional 98 shares in the last quarter. Credit Suisse AG boosted its position in shares of Juno Therapeutics by 51.1% in the third quarter. Credit Suisse AG now owns 187,262 shares of the biopharmaceutical company’s stock valued at $5,621,000 after buying an additional 63,346 shares in the last quarter. Candriam Luxembourg S.C.A. purchased a new position in shares of Juno Therapeutics during the third quarter valued at $2,401,000. Finally, Bamco Inc. NY boosted its position in shares of Juno Therapeutics by 340.8% in the third quarter. Bamco Inc. NY now owns 443,107 shares of the biopharmaceutical company’s stock valued at $13,298,000 after buying an additional 342,582 shares in the last quarter.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

5 Day Chart for NASDAQ:JUNO

Receive News & Ratings for Juno Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.